Literature DB >> 14981513

VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo.

Elizabeth A Harrington1, David Bebbington, Jeff Moore, Richele K Rasmussen, Abi O Ajose-Adeogun, Tomoko Nakayama, Joanne A Graham, Cecile Demur, Thierry Hercend, Anita Diu-Hercend, Michael Su, Julian M C Golec, Karen M Miller.   

Abstract

The Aurora kinases are essential for the regulation of chromosome segregation and cytokinesis during mitosis. Aberrant expression and activity of these kinases occur in a wide range of human tumors, and lead to aneuploidy and tumorigenesis. Here we report the discovery of a highly potent and selective small-molecule inhibitor of Aurora kinases, VX-680, that blocks cell-cycle progression and induces apoptosis in a diverse range of human tumor types. This compound causes profound inhibition of tumor growth in a variety of in vivo xenograft models, leading to regression of leukemia, colon and pancreatic tumors at well-tolerated doses. Our data indicate that Aurora kinase inhibition provides a new approach for the treatment of multiple human malignancies.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14981513     DOI: 10.1038/nm1003

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  299 in total

1.  Relationship between quantitative GRB7 RNA expression and recurrence after adjuvant anthracycline chemotherapy in triple-negative breast cancer.

Authors:  Joseph A Sparano; Lori J Goldstein; Barrett H Childs; Steven Shak; Diana Brassard; Sunil Badve; Frederick L Baehner; Roberto Bugarini; Steve Rowley; Edith A Perez; Lawrence N Shulman; Silvana Martino; Nancy E Davidson; Paraic A Kenny; George W Sledge; Robert Gray
Journal:  Clin Cancer Res       Date:  2011-09-20       Impact factor: 12.531

Review 2.  The spindle checkpoint: a quality control mechanism which ensures accurate chromosome segregation.

Authors:  Stephen S Taylor; Maria I F Scott; Andrew J Holland
Journal:  Chromosome Res       Date:  2004       Impact factor: 5.239

3.  The induction of polyploidy or apoptosis by the Aurora A kinase inhibitor MK8745 is p53-dependent.

Authors:  Jayasree S Nair; Alan L Ho; Gary K Schwartz
Journal:  Cell Cycle       Date:  2012-02-15       Impact factor: 4.534

4.  An integrated pharmacokinetic-pharmacodynamic model for an Aurora kinase inhibitor.

Authors:  Hiroko Kamei; Robert C Jackson; Daniella Zheleva; Fordyce A Davidson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2010-08-08       Impact factor: 2.745

Review 5.  Current status of molecularly targeted therapy for hepatocellular carcinoma: basic science.

Authors:  Shinji Tanaka; Shigeki Arii
Journal:  Int J Clin Oncol       Date:  2010-05-27       Impact factor: 3.402

Review 6.  Aurora kinase inhibitors as anticancer molecules.

Authors:  Hiroshi Katayama; Subrata Sen
Journal:  Biochim Biophys Acta       Date:  2010-09-20

7.  Some insights into the binding mechanism of Aurora B kinase gained by molecular dynamics simulation.

Authors:  Rui Xiong; Xiao-Mei Cai; Jing Wei; Peng-Yu Ren
Journal:  J Mol Model       Date:  2012-05-30       Impact factor: 1.810

8.  Aneugen Molecular Mechanism Assay: Proof-of-Concept With 27 Reference Chemicals.

Authors:  Derek T Bernacki; Steven M Bryce; Jeffrey C Bemis; Stephen D Dertinger
Journal:  Toxicol Sci       Date:  2019-08-01       Impact factor: 4.849

9.  Targeted approach to metastatic colorectal cancer: what comes beyond epidermal growth factor receptor antibodies and bevacizumab?

Authors:  Teresa Troiani; Erika Martinelli; Floriana Morgillo; Anna Capasso; Anna Nappi; Vincenzo Sforza; Fortunato Ciardiello
Journal:  Ther Adv Med Oncol       Date:  2013-01       Impact factor: 8.168

10.  Mitotic MELK-eIF4B signaling controls protein synthesis and tumor cell survival.

Authors:  Yubao Wang; Michael Begley; Qing Li; Hai-Tsang Huang; Ana Lako; Michael J Eck; Nathanael S Gray; Timothy J Mitchison; Lewis C Cantley; Jean J Zhao
Journal:  Proc Natl Acad Sci U S A       Date:  2016-08-15       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.